Viewing nowGlezon Tablets (Pioglitazone Hydrochloride)
Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Samjin Pharmaceutical Co., Ltd.

MFDS item code 200702697 · Notified 2007.03.05 · Insurance code 647800120
Improvement of glycemic control in type 2 diabetes mellitus
This drug is used along with diet and exercise therapy to help control blood sugar levels in patients with type 2 diabetes. It can be administered as monotherapy, and if there is no blood sugar improvement despite the use of other oral hypoglycemic agents, it can be given in combination with sulfonylureas, metformin, or insulin. Additionally, nutritional counseling and weight loss may be necessary for patients with type 2 diabetes, and exercise therapy must also be implemented. Such therapeutic efforts are crucial not only for initial treatment but also for maintaining drug efficacy. Therefore, this drug is used to improve blood sugar control in patients with type 2 diabetes.
This medicine is administered orally once daily, regardless of meals. Patients with diabetes should receive treatment for an adequate period to evaluate changes in glycated hemoglobin (at least 3 months), provided that glycemic control does not worsen. 1. Monotherapy This medicine may be initiated as monotherapy at 15 mg of pioglitazone once daily in patients whose blood glucose is not adequately controlled with diet and exercise. If an adequate effect is not achieved with the initial dose of this medicine, the dose may be increased to 30 mg once daily. Combination therapy should be considered for patients who do not respond adequately to monotherapy. 2. Combination therapy 1) Sulfonylurea: This medicine may be administered in combination with a sulfonylurea; the initial dose is 15 mg once daily. When used in combination with this medicine, the current sulfonylurea may be continued at the same dosage and administration schedule. However, if the patient develops symptoms of hypoglycemia, the sulfonylurea dose should be reduced. 2) Metformin: This medicine may be administered in combination with metformin; the initial dose is 15 mg once daily. When used in combination with this medicine, the current metformin may be continued at the same dosage and administration schedule. It is unlikely that the metformin dose will need to be adjusted due to symptoms of hypoglycemia during combination therapy with this medicine. 3) Insulin: This medicine may be administered in combination with insulin; the dose is 15 mg once daily. The current insulin dose may be continued when combination therapy with this medicine is initiated. However, if a patient receiving this medicine in combination with insulin develops symptoms of hypoglycemia or the plasma glucose concentration decreases to 100 mg/dL or less, the insulin dose may be reduced by 10 ~ 25 %. Subsequent dose adjustments should be individualized according to the degree of glycemic control. • Maximum recommended dose For monotherapy or combination therapy with a sulfonylurea, metformin, or insulin, doses exceeding 30 mg once daily are not recommended. Dose adjustment is not recommended in patients with renal insufficiency (refer to the Precautions section, Patients with Renal Impairment). Do not initiate treatment with this medicine if, at the start of therapy, the patient has clinical evidence of active liver disease or elevated serum aminotransferase levels (ALT at least 2.5 times the upper limit of normal) (refer to Adverse Reactions and Precautions, Effects on the Liver). Monitoring of liver enzymes is recommended in all patients before starting treatment with this medicine and periodically thereafter. There are no data on the use of this medicine in combination therapy with another thiazolidinedione.
Use is not recommended in children under 18 years of age because there is no experience with its use in this age group.
This drug is a medication that helps control blood sugar levels in patients with type 2 diabetes. It should not be used in patients with heart failure or a history of heart failure, as it may put a burden on the heart during administration. This drug can cause fluid retention, aggravating edema or heart failure, so if sudden weight gain or symptoms of heart failure such as shortness of breath occur, medical personnel should be notified immediately. Patients with active bladder cancer or a history of bladder cancer should also avoid this medication, and if symptoms such as hematuria or urinary disorders appear during treatment, they must report to a doctor immediately. Patients with poor liver function or severe renal impairment should avoid taking this medication, and it is advisable for women who are pregnant or may become pregnant not to use it. When used in combination with other diabetes medications, the risk of hypoglycemia may increase, so patients should be aware of hypoglycemia symptoms and management, and dosage adjustments of concomitant medications may be necessary. Regular blood sugar and liver function tests should be conducted while taking this medication, and if any abnormal symptoms such as sudden weight gain, edema, shortness of breath, or vision changes occur, immediate consultation with medical personnel is recommended. Additionally, premenopausal women should use appropriate contraception as this medication may stimulate ovulation, increasing the risk of pregnancy. Older adults or patients with impaired kidney function should use this medication cautiously, and in case of drug overdose, appropriate treatment should be sought immediately at a hospital. Finally, the safety and efficacy of this drug have not been established in children, therefore it is not used in pediatric patients.
Congestive heart failure, excessive and rapid weight change, dyspnea, edema, fluid retention, edema, upper respiratory infection, headache, sinusitis, myalgia, pharyngitis, abdominal distension, weight gain, hypoglycemia, urinary tract infection, low back pain, dizziness, diarrhea, elevated serum creatine kinase, hypertension, heart failure, limb pain, low back pain, chest pain, death due to cardiovascular factors, hospitalization due to exacerbation of congestive heart failure, emergency room visit due to congestive heart failure, weight gain, elevated serum ALT levels, elevated serum bilirubin levels, diabetic macular edema accompanied by vision reduction, fatal and non-fatal liver failure, edema, weight gain, hypoglycemia, dizziness, upper respiratory infection, increased blood sugar, elevated ALT/AST, loss of appetite, constipation, upper abdominal pain, headache, chest pain, fatigue, weakness, dyspepsia, nausea, dyspnea, itching, chest discomfort, tremor, chills, gastrointestinal disease, abdominal pain, epigastric discomfort, numbness, muscle stiffness, head discomfort, increased liver enzymes, worsening of liver disease, hives, eczema, arthralgia, knee abnormalities, arm weakness, proteinuria, increased serum creatinine, anxiety, insomnia, drowsiness, simple herpes, blurred vision, hypertension, cardiac dysfunction, orthostatic hypotension, palpitations, stroke, sexual dysfunction, myocardial infarction, abdominal pain, cardiac dysfunction, fracture
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a container that protects it from light and air, and in a dry place. The recommended storage temperature is between 15 and 30 degrees Celsius, with 25 degrees Celsius being the most suitable.
White to grayish round and convex tablets
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Celltrion Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 33.06mg
Tablet · Prescription medication
Celltrion Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Dongwha Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Hanol Bio Pharma Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Kujoo Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Kyungdong Pharm Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.